Otamixaban
| Title | Journal |
|---|---|
| New parenteral anticoagulants: focus on factor Xa and thrombin inhibitors. | Current drug discovery technologies 20120601 |
| Emerging anticoagulants. | Current medicinal chemistry 20120101 |
| Inhibitors of propagation of coagulation: factors V and X. | British journal of clinical pharmacology 20111001 |
| New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome. | Pharmacotherapy 20111001 |
| Is there evidence to support the use of direct Factor Xa inhibitors in coronary artery disease? | Reviews on recent clinical trials 20110501 |
| Future anticoagulants in interventional cardiology: anti-IXa and anti-Xa agents in percutaneous coronary intervention. | Future cardiology 20110501 |
| Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes. | Expert opinion on investigational drugs 20110401 |
| New parenteral anticoagulants in development. | Therapeutic advances in cardiovascular disease 20110201 |
| New anticoagulant agents in acute coronary syndromes. | Heart (British Cardiac Society) 20110201 |
| A network-based multi-target computational estimation scheme for anticoagulant activities of compounds. | PloS one 20110101 |
| Emerging therapies for acute coronary syndromes. | Frontiers in pharmacology 20110101 |
| Clinical pharmacology of direct and indirect factor Xa inhibitors. | Drugs 20101112 |
| Factor Xa inhibitors: next-generation antithrombotic agents. | Journal of medicinal chemistry 20100909 |
| What goes into a major acute coronary syndrome trial and what will future trials look like? | Current cardiology reports 20100701 |
| Recent research on antithrombotics. News on the treatment of patients with acute coronary syndromes. | Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology 20100501 |
| New drugs for the treatment of coronary artery syndromes: otamixaban and ticagrelor. | Expert opinion on pharmacotherapy 20100201 |
| Post-operative thromboprophylaxis: new oral thrombin and factor X inhibitors and their place in clinical practice. | F1000 medicine reports 20100101 |
| Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. | Lancet (London, England) 20090905 |
| Otamixaban in acute coronary syndromes. | Lancet (London, England) 20090905 |
| [What's new on antithrombotics?]. | Annales de cardiologie et d'angeiologie 20090801 |
| [Factor Xa-inhibition in interventional cardiology]. | Hamostaseologie 20071201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20070901 |
| Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. | Circulation 20070522 |
| The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development. | Current medicinal chemistry 20070101 |
| Drug evaluation: the directly activated Factor Xa inhibitor otamixaban. | IDrugs : the investigational drugs journal 20061201 |
| Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease. | Clinical pharmacology and therapeutics 20061201 |
| Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. | Expert opinion on investigational drugs 20060801 |
| Asymmetric synthesis of intermediates for otamixaban and premafloxacin by the chiral ligand-controlled asymmetric conjugate addition of a lithium amide. | The Journal of organic chemistry 20060609 |
| Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, and acetylsalicylic acid. | Thrombosis and haemostasis 20060201 |
| Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposure. | Journal of clinical pharmacology 20060101 |
| Pharmacokinetic/pharmacodynamic relationships for otamixaban, a direct factor Xa inhibitor, in healthy subjects. | Journal of clinical pharmacology 20060101 |
| Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor. | Thrombosis and haemostasis 20051201 |
| Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, with tirofiban in healthy volunteers. | Thrombosis and haemostasis 20050401 |
| Small molecule coagulation cascade inhibitors in the clinic. | Current topics in medicinal chemistry 20050101 |
| Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity. | Bioorganic & medicinal chemistry letters 20020617 |
| Pharmacological characterization of a novel factor Xa inhibitor, FXV673. | Thrombosis research 20010815 |
| Role of short-term inhibition of factor Xa by FXV673 in arterial passivation: a study in a chronic model of thrombosis in conscious dogs. | Journal of cardiovascular pharmacology 20010801 |
| Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis. | British journal of pharmacology 20010801 |